To The Moon
Home
News
TigerAI
Log In
Sign Up
ccyang82
+Follow
Posts · 7
Posts · 7
Following · 0
Following · 0
Followers · 0
Followers · 0
ccyang82
ccyang82
·
2021-02-07
Nooo
Sorry, this post has been deleted
看
1.95K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-07
Vaccine
U.S. FDA gearing up for rapid review of potential COVID-19 booster shots
(Reuters) - The U.S. Food and Drug Administration is planning a rapid review process for quick turna
U.S. FDA gearing up for rapid review of potential COVID-19 booster shots
看
2.31K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-07
Not environmental friendly
Sorry, this post has been deleted
看
1.85K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-07
Botcoim
Sorry, this post has been deleted
看
2.04K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-04
Yes
Sorry, this post has been deleted
看
2.19K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-04
Woo
Sorry, this post has been deleted
看
2.91K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
ccyang82
ccyang82
·
2021-02-04
Good results
Nokia's fourth-quarter revenue beat expectations
HELSINKI, Feb 4 (Reuters) - Finnish telecom network equipment maker Nokia on Thursday reported bette
Nokia's fourth-quarter revenue beat expectations
看
1.72K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Load more
No following yet
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3558759734550648","uuid":"3558759734550648","gmtCreate":1595666691929,"gmtModify":1691167185950,"name":"ccyang82","pinyin":"ccyang82","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":20,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":389052384,"gmtCreate":1612633623448,"gmtModify":1704873298011,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Nooo","listText":"Nooo","text":"Nooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389052384","repostId":"1189425388","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389052993,"gmtCreate":1612633558712,"gmtModify":1704873297685,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Vaccine","listText":"Vaccine","text":"Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389052993","repostId":"1152247545","repostType":4,"repost":{"id":"1152247545","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612512116,"share":"https://ttm.financial/m/news/1152247545?lang=en_US&edition=fundamental","pubTime":"2021-02-05 16:01","market":"us","language":"en","title":"U.S. FDA gearing up for rapid review of potential COVID-19 booster shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1152247545","media":"Reuters","summary":"(Reuters) - The U.S. Food and Drug Administration is planning a rapid review process for quick turna","content":"<p>(Reuters) - The U.S. Food and Drug Administration is planning a rapid review process for quick turnaround of new COVID-19 booster shots if variants of the coronavirus emerge against which the vaccines do not provide protection, the agency’s top official said on Thursday.</p>\n<p>Dr. Janet Woodcock, acting commissioner of the FDA, said that if new variants of the coronavirus emerge that require booster shots or changes to vaccines, the agency will not require the type of large trials that were required for emergency use authorization or approval.</p>\n<p>The agency plans to issue a proposal on the process for public comment in a few weeks, she said during a press briefing. That process will likely require safety information as well as, if possible, the convening of an outside committee of experts to review the booster shot.</p>\n<p>Both Pfizer Inc and German partner BioNTech SE as well as Moderna Inc, whose vaccines have been authorized for emergency use in the United States, have said they are preparing for the possibility that variants will emerge that could require a booster shot.</p>\n<p>The current vaccines still provide adequate protection against existing variants of concern, Woodcock said. A variant in the U.K. has been found to be more transmissible while some vaccines have been found to be less effective against variants that emerged in South Africa and Brazil.</p>\n<p>Settling on a regulatory process will help the FDA move quickly if needed, she said.</p>\n<p>“If the virus changes, we are getting prepared for that,” Woodcock said.</p>\n<p>The threshold for deciding on whether a new vaccine is needed has not yet been determined. Countries must build surveillance measures to find variants of concerns, and then scientists must agree upon at what point a variant has strayed too far from the unaltered virus and requires a new vaccine.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA gearing up for rapid review of potential COVID-19 booster shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA gearing up for rapid review of potential COVID-19 booster shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-05 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - The U.S. Food and Drug Administration is planning a rapid review process for quick turnaround of new COVID-19 booster shots if variants of the coronavirus emerge against which the vaccines do not provide protection, the agency’s top official said on Thursday.</p>\n<p>Dr. Janet Woodcock, acting commissioner of the FDA, said that if new variants of the coronavirus emerge that require booster shots or changes to vaccines, the agency will not require the type of large trials that were required for emergency use authorization or approval.</p>\n<p>The agency plans to issue a proposal on the process for public comment in a few weeks, she said during a press briefing. That process will likely require safety information as well as, if possible, the convening of an outside committee of experts to review the booster shot.</p>\n<p>Both Pfizer Inc and German partner BioNTech SE as well as Moderna Inc, whose vaccines have been authorized for emergency use in the United States, have said they are preparing for the possibility that variants will emerge that could require a booster shot.</p>\n<p>The current vaccines still provide adequate protection against existing variants of concern, Woodcock said. A variant in the U.K. has been found to be more transmissible while some vaccines have been found to be less effective against variants that emerged in South Africa and Brazil.</p>\n<p>Settling on a regulatory process will help the FDA move quickly if needed, she said.</p>\n<p>“If the virus changes, we are getting prepared for that,” Woodcock said.</p>\n<p>The threshold for deciding on whether a new vaccine is needed has not yet been determined. Countries must build surveillance measures to find variants of concerns, and then scientists must agree upon at what point a variant has strayed too far from the unaltered virus and requires a new vaccine.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6e474d690ea02c536f0fd4c03fc3ddef","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152247545","content_text":"(Reuters) - The U.S. Food and Drug Administration is planning a rapid review process for quick turnaround of new COVID-19 booster shots if variants of the coronavirus emerge against which the vaccines do not provide protection, the agency’s top official said on Thursday.\nDr. Janet Woodcock, acting commissioner of the FDA, said that if new variants of the coronavirus emerge that require booster shots or changes to vaccines, the agency will not require the type of large trials that were required for emergency use authorization or approval.\nThe agency plans to issue a proposal on the process for public comment in a few weeks, she said during a press briefing. That process will likely require safety information as well as, if possible, the convening of an outside committee of experts to review the booster shot.\nBoth Pfizer Inc and German partner BioNTech SE as well as Moderna Inc, whose vaccines have been authorized for emergency use in the United States, have said they are preparing for the possibility that variants will emerge that could require a booster shot.\nThe current vaccines still provide adequate protection against existing variants of concern, Woodcock said. A variant in the U.K. has been found to be more transmissible while some vaccines have been found to be less effective against variants that emerged in South Africa and Brazil.\nSettling on a regulatory process will help the FDA move quickly if needed, she said.\n“If the virus changes, we are getting prepared for that,” Woodcock said.\nThe threshold for deciding on whether a new vaccine is needed has not yet been determined. Countries must build surveillance measures to find variants of concerns, and then scientists must agree upon at what point a variant has strayed too far from the unaltered virus and requires a new vaccine.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389056780,"gmtCreate":1612633517740,"gmtModify":1704873297522,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Not environmental friendly","listText":"Not environmental friendly","text":"Not environmental friendly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389056780","repostId":"1161551882","repostType":4,"isVote":1,"tweetType":1,"viewCount":1848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389056441,"gmtCreate":1612633494183,"gmtModify":1704873297359,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Botcoim","listText":"Botcoim","text":"Botcoim","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389056441","repostId":"1161551882","repostType":4,"isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317147928,"gmtCreate":1612431401464,"gmtModify":1704871074140,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317147928","repostId":"2108479191","repostType":4,"isVote":1,"tweetType":1,"viewCount":2192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317145586,"gmtCreate":1612431346545,"gmtModify":1704871072183,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317145586","repostId":"2108799957","repostType":4,"isVote":1,"tweetType":1,"viewCount":2911,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317142433,"gmtCreate":1612431290222,"gmtModify":1704871071045,"author":{"id":"3558759734550648","authorId":"3558759734550648","name":"ccyang82","avatar":"https://community-static.tradeup.com/news/fd3e44b537c4f2305efc784bd2ff4254","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3558759734550648","idStr":"3558759734550648"},"themes":[],"htmlText":"Good results","listText":"Good results","text":"Good results","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317142433","repostId":"2108790331","repostType":4,"repost":{"id":"2108790331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612419199,"share":"https://ttm.financial/m/news/2108790331?lang=en_US&edition=fundamental","pubTime":"2021-02-04 14:13","market":"us","language":"en","title":"Nokia's fourth-quarter revenue beat expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2108790331","media":"Reuters","summary":"HELSINKI, Feb 4 (Reuters) - Finnish telecom network equipment maker Nokia on Thursday reported bette","content":"<p>HELSINKI, Feb 4 (Reuters) - Finnish telecom network equipment maker Nokia on Thursday reported better-than-expected fourth-quarter revenue amid a strategy revamp from new CEO Pekka Lundmark.</p>\n<p>Nokia said its October-December revenue fell 5% to 6.57 billion euros, beating a consensus figure of 6.42 billion, Refinitiv Eikon data showed.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nokia's fourth-quarter revenue beat expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNokia's fourth-quarter revenue beat expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-04 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HELSINKI, Feb 4 (Reuters) - Finnish telecom network equipment maker Nokia on Thursday reported better-than-expected fourth-quarter revenue amid a strategy revamp from new CEO Pekka Lundmark.</p>\n<p>Nokia said its October-December revenue fell 5% to 6.57 billion euros, beating a consensus figure of 6.42 billion, Refinitiv Eikon data showed.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9bc0118e35c2c3a2c9e015f33f2d4de8","relate_stocks":{"NOK":"诺基亚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108790331","content_text":"HELSINKI, Feb 4 (Reuters) - Finnish telecom network equipment maker Nokia on Thursday reported better-than-expected fourth-quarter revenue amid a strategy revamp from new CEO Pekka Lundmark.\nNokia said its October-December revenue fell 5% to 6.57 billion euros, beating a consensus figure of 6.42 billion, Refinitiv Eikon data showed.","news_type":1,"symbols_score_info":{"NOK":0.9}},"isVote":1,"tweetType":1,"viewCount":1723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}